IPECAD Modeling Workshop 2023 Cross-Comparison Challenge on Cost-Effectiveness Models in Alzheimer's Disease.
Handels R, Herring WL, Kamgar F, Aye S, Tate A, Green C, Gustavsson A, Wimo A, Winblad B, Sköldunger A, Raket LL, Stellick CB, Spackman E, Hlávka J, Wei Y, Mar J, Soto-Gordoa M, de Kok I, Brück C, Anderson R, Pemberton-Ross P, Urbich M, Jönsson L.
Handels R, et al.
Value Health. 2024 Oct 8:S1098-3015(24)02857-2. doi: 10.1016/j.jval.2024.09.006. Online ahead of print.
Value Health. 2024.
PMID: 39384068
Free article.
OBJECTIVES: Decision-analytic models assessing the value of emerging Alzheimer's disease (AD) treatments are challenged by limited evidence on short-term trial outcomes and uncertainty in extrapolating long-term patient-relevant outcomes. ...
OBJECTIVES: Decision-analytic models assessing the value of emerging Alzheimer's disease (AD) treatments are challenged by limited ev …